Advera Health Analytics Launches Clinical Meta-Analysis in Evidex Platform

Share Article

Powered by Advera’s proprietary 14,000+ clinical trial safety results database, new cloud-based analytic replicates costly meta-analysis studies.

Advera Health Analytics, Inc., a global leader in pharmacovigilance software, analytics, and data at the leading edge of drug safety science, today announced the launch of Clinical Meta-Analysis in Evidex®. This new analytical tool allows drug safety, epidemiology, and medical affairs departments of all sizes to perform on demand meta-analyses of safety issues using a cloud-based software-as-a-service platform.

The proprietary Advera Clinical Evidence database powers the new analytic tool and is backed by the results of 14,000+ randomized clinical trials. This allows users to quickly and seamlessly determine the pooled adverse event rates, odds ratios and p values for safety issues of interest.

These rates can be determined for specific drugs, drug combinations, or for a list of drugs within a class, indication or mechanisms of action. Adverse events rates can be aggregated at MedDRA defined system organ class (SOC), standardized medical query (SMQ), or preferred term (PT) levels. These customized results help to characterize and determine expectedness of adverse events, better understand the safety market landscape, and quickly hypothesize potential safety differentiators.

The Advera Clinical Evidence database is a first-of-its-kind safety focused clinical trial outcomes database, only available in Evidex. It contains the safety outcomes and adverse events from over 14,000 clinical trials, sourced from and supplemented with results from published studies and poster presentations at medical conferences. The data are collected via a combination of natural language processing (NLP) and AI-enabled human curators.

“We’re very excited to launch the Clinical Meta-Analysis tool,” said Robert Kyle, Chief Product Officer of Advera Health Analytics. “Traditionally, safety related meta-analyses have been costly, taken significant time to produce and can often miss relevant studies. With today’s launch of Clinical Meta-Analysis in Evidex, users can now run complex searches of safety issues using intuitive Boolean connectors with a few clicks of the mouse. This will save our clients significant time and cost before choosing to conduct a full-fledged study.”

In addition to replicating meta-analysis studies, with the launch of the Clinical Meta-Analysis capability, Evidex users can combine the results with data from spontaneous reporting databases like the FDA Adverse Event Reporting System (FAERS), the Uppsala Monitoring Centre’s VigiBase, or a client’s internal global safety database in a single platform. It creates efficient signal detection, validation, and assessment procedures further freeing up time and resources.

For those interested in learning more, Advera Health has set up an information and inquiry web site specifically for Clinical Meta-Analysis in Evidex:

Advera Health will be demonstrating Clinical Meta-Analysis in Evidex at the ISPE 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) taking place on August 24-28, 2019 at the Pennsylvania Convention Center in Philadelphia, PA.

About Evidex
Advera Health’s Evidex is a cloud-based signal detection and management platform that provides powerful insights using Advera Health’s curated out-of-the-box data, structured internal ICSR data, and alternative safety data sources such as claims, EHR, and social media. Powered by the proprietary RxFilter® data optimization technology, Evidex supports a broad array of safety signal detection and risk mitigation use cases.

About Advera Health Analytics
Advera Health Analytics is a global leader in pharmacovigilance software, analytics, and data at the leading edge of drug safety science. Founded by a group of passionate healthcare entrepreneurs, Advera Health’s mission is to mitigate risk in the healthcare system by improving the transparency and actionability of drug safety data through the curation and aggregation of large disparate datasets and the application of proprietary analytics. Please visit as well as our newsroom, blog, Twitter, and LinkedIn pages for more information about the company.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brian Overstreet
since: 03/2011
Follow >
Visit website